Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)

Trial Profile

Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial-wrinkles; Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 18 Dec 2017 Accoridng to a Allergan media release, based on the data of this and other phase III trial (250237), Vistabel (botulinum toxin type A) received a positive opinion from ANSM (France) for the temporary treatment of moderate to severe forehead lines in adult patients in 30 European countries.
    • 19 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Sep 2016.
    • 28 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top